PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 2016-01-01
- Employees
- -
- Market Cap
- -
- Website
- https://www.parkerici.org/
Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- Drug: NKTR-214 (Cohort A)Drug: CDX-301 (Cohort B and C)Radiation: Stereotactic body radiation therapy (SBRT) (Cohort B)Drug: INO-5151 (Cohort C)Device: Cellectra 2000
- First Posted Date
- 2019-02-08
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- Parker Institute for Cancer Immunotherapy
- Target Recruit Count
- 43
- Registration Number
- NCT03835533
- Locations
- 🇺🇸
Angeles Clinic, Los Angeles, California, United States
🇺🇸University of California San Francisco, San Francisco, California, United States
🇺🇸Oregon Health & Science University, Portland, Oregon, United States
Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome Intervention
- Conditions
- Metastatic Melanoma
- Interventions
- Drug: Placebo for antibioticDrug: Matching Placebo for SER-401
- First Posted Date
- 2019-01-25
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- Parker Institute for Cancer Immunotherapy
- Target Recruit Count
- 14
- Registration Number
- NCT03817125
- Locations
- 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Nivolumab With or Without Ipilimumab in Advanced Metastatic Cancer
- Conditions
- Advanced Metastatic CancerAdvanced Prostate Cancer
- Interventions
- Biological: Nivolumab MonotherapyBiological: Nivolumab and Ipilimumab (5 mg/kg) Combination for Prostate CancerBiological: Nivolumab and Ipilimumab and Combination for Metastatic CancerBiological: Nivolumab and Ipilimumab (3 mg/kg) Combination for Prostate Cancer
- First Posted Date
- 2018-08-29
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- Parker Institute for Cancer Immunotherapy
- Target Recruit Count
- 100
- Registration Number
- NCT03651271
- Locations
- 🇺🇸
University of California, Los Angeles, Los Angeles, California, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma
- Conditions
- Metastatic Pancreatic Adenocarcinoma
- Interventions
- First Posted Date
- 2017-07-11
- Last Posted Date
- 2022-12-23
- Lead Sponsor
- Parker Institute for Cancer Immunotherapy
- Target Recruit Count
- 129
- Registration Number
- NCT03214250
- Locations
- 🇺🇸
University of California, Los Angeles, Los Angeles, California, United States
🇺🇸M.D. Anderson Cancer Center, Houston, Texas, United States
🇺🇸Stanford University, Stanford, California, United States
Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy
- First Posted Date
- 2016-04-07
- Last Posted Date
- 2022-12-23
- Lead Sponsor
- Parker Institute for Cancer Immunotherapy
- Target Recruit Count
- 20
- Registration Number
- NCT02731729
- Locations
- 🇺🇸
Lehigh Valley Health Network, Allentown, Pennsylvania, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States